Improving TDF-FTC uptake among US young men who have sex with men on HIV PrEP could yield substantial 10-year value, while a hypothetical study eliminating adverse event uncertainty would not change the...
In two phase 3, double-blind, placebo-controlled trials of adults with noncirrhotic chronic hepatitis B virus infection receiving stable nucleoside or nucleotide analog therapy, 24 weeks of bepirovirsen...
The FDA approved tebipenem pivoxil (Utebzi) for adults with complicated urinary tract infections, including pyelonephritis, who have limited or no alternative oral treatment options.
The FDA approved expanded adjuvant therapy options for adults with renal cell carcinoma with a clear cell component who are at intermediate-high or high risk of recurrence after nephrectomy, with or without...
IgG4-related disease is unlikely to be the first diagnosis suspected in primary care, but PCPs may be the first clinicians to recognize the atypical, recurrent, mass-like, or multiorgan patterns that should...
The FDA approved ensitrelvir (Xocova) for post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older following contact with an individual with COVID-19.
In the phase 3a REIMAGINE 1 trial, once-weekly cagrilintide–semaglutide reduced HbA1c vs placebo at 40 weeks in adults with early-stage type 2 diabetes that was inadequately controlled with diet and...
ACOG’s 2026 maternal immunization schedule outlines vaccine recommendations before, during, and after pregnancy, including influenza, COVID-19, Tdap, and RSV vaccination.
